Misaligned incentives
Innovators expect adoption; clinics expect a finished, validated product. Both lose in the gap between.
Reproductive Health Research Institute
Rigorous Science.
Real-World Impact.
We validate new reproductive-health technology in real clinics — testing whether it actually works at scale, holds up economically, and improves care — so only innovation that earns it reaches patients.
Contents
01 — ProblemA broken path from lab to clinic
02 — MethodThe four-pillar framework
03 — ProcessPrototype to practice
04 — NetworkDecentralized & independent
01
The path from lab to clinic is broken.
The field is producing real breakthroughs — AI embryo assessment, microfluidics, genomics. Most of it stalls before it ever reaches a patient.
No shared standard
Nothing independent validates a technology before market entry, so marketing outruns the evidence.
Clinics carry the risk
Good ideas die from adoption friction while mediocre ones survive on a sales deck.
Summary
Start-ups spend scarce capital paying clinics to trial products that often arrive dead on launch. Clinics absorb the risk of unproven tools. Patients get inconsistent care with no clear quality signal.
02
What RHRI is.
Not a regulator, a lab, or a consultancy. Independent validation infrastructure.
A decentralized network of clinics where new technology is tested under real operating conditions, against one shared standard — and the results are published.
We validate, connect, and standardize. We complement the ecosystem rather than compete with it.
What we are not
- A regulatory body
- A single research lab
- A commercial consultancy
- A gatekeeper
03
The Four-Pillar Framework.
Every technology is assessed on four dimensions at once. Most evaluations test only the first. We test all four.
Assessment Scorecard
FORM RHRI-4P · APPLIED TO EVERY TECHNOLOGY
01
Replicability
Do results hold across operators, labs, and geographies?
Evaluated for
- Intra-operator consistency
- Inter-operator validation
- Protocol clarity & quality control
02
Scalability
Does it work at clinic volume and across real workforce skill levels?
Evaluated for
- Function at clinic-level volume
- Tolerance to skill distribution
- Does scale improve or break consistency?
03
Sustainability
Do performance and unit economics hold as volume grows?
Evaluated for
- Unit economics at scale
- Operational load on the clinic
- Viability without long-term strain
04
Patient Value
The only measure that ultimately counts.
Evaluated for
- Lower cost & better outcomes
- Shorter time-to-baby
- Wider, more equitable access
Pass requires evidence across all four pillars.
RHRI-VALIDATED ▢
04
From prototype to practice.
A clear path. Durations are typical, not guaranteed.
STEP01
Review
We assess the technology, its stage, and what validation would need to prove.
≈ 2–4 weeks
STEP02
Protocol
We design the study, define endpoints, and match it to clinics in the network.
≈ 4–6 weeks
STEP03
Multi-site validation
Tested across clinics, geographies, and operator skill levels under real conditions.
≈ 3–6 months
STEP04
Evidence
Outcomes, economics, and operational fit measured against the four pillars — and published.
≈ 4–8 weeks
STEP05
Implementation
SOPs, training, and rollout support for what earns it.
Ongoing
05
Who we serve.
One standard, four stakeholders, aligned around evidence.
A path that earns trust
Credible, real-world validation clinics trust — a faster, lower-cost route from prototype to adoption than buying trials one clinic at a time.
Proven before you adopt
First access to technology that's actually been proven, with the protocols and support to adopt it — and far less risk.
The reason the standard exists
RHRI-validated means proven to improve outcomes, reduce cost, or widen access in the real world.
Investment that pays off
Infrastructure that grows the market, speeds translation, and separates signal from noise.
06
Areas of innovation.
Four verticals, one framework. Every category runs through the same four pillars.
VERTICAL A
Software
AI and digital tools across the workflow: embryo assessment, follicle counting, decision support, predictive analytics.
VERTICAL B
Hardware
Devices that add precision and consistency: robotics, microfluidics, imaging, cryostorage, environmental monitoring.
VERTICAL C
Process
Re-engineering how care is delivered: lab workflow, routing, protocol integration, quality systems.
VERTICAL D
Biotech
Anything needing clinical evidence: culture media, supplements, genetic testing (PGT), biomarkers, novel culture systems.
07
Operating model & principles.
Independence is the product. Without it, validation is worthless.
Decentralized by design
No single headquarters. Talent and partners are distributed; pilots run where conditions are best. Transparent funding, diverse governance, and published methodology keep the standard honest.
What guides us
- 01 Evidence over enthusiasm.
- 02 Collaboration over competition.
- 03 Impact over publications.
- 04 Transparency by default.
- 05 Pragmatism over perfection.
08
Three-year direction.
Foundation, then network, then standard.
2026
Phase 01 — Foundation
Stand it up
Establish governance and the founding team. Build the validation protocols. Run the first studies and publish the methodology.
2027
Phase 02 — Network
Grow the network
Expand the partner-clinic network. Launch membership and the validation registry. Reach sustainability.
2028
Phase 03 — Standard
Become the standard
"RHRI-validated" becomes a recognized mark of quality. Influence guidelines; launch education and certification.
09
Team.
Science, medicine, and clinical operations.
DM
Daniel Madero
Founder & Director
Fertility executive focused on scaling clinics and building operating models across the Americas and Europe. Former CEO of Fertilidad Integral; senior advisor to RHEA and GenPrime.
CH
Cynthia Hudson
Clinical Strategy
SVP of Clinics at TMRW Life Sciences. Embryologist and medical technologist with 20+ years in reproductive medicine. Founder of NOVA Genomics; owner of Perch Fertility, New Jersey.
FA
Felicitas Azpiroz
Research & Science
Reproductive scientist at the Universitat Autònoma de Barcelona (UAB), working within the Eugin Group research ecosystem — bridging rigorous lab science and clinically relevant questions.
Advisory board and partner network are in formation, and shown as such — never invented.
Get involved
This is the foundation.
This is the foundation.
Now we build.
Innovator, clinic, researcher, or funder — if you want validation to mean something, let's talk.